Special Issue "Hodgkin's Lymphoma"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 March 2018)
Prof. Dr. Hans Knecht
1. Division of Hematology, Department of Medicine, McGill University, Montréal, Québec H3T 1E2, Canada
2. Division d'Hématologie, Département de Médecine, CHUS, Université de Sherbrooke, Québec, J1H 5N4, Canada
Website | E-Mail
Interests: PCR; cell culture; DNA; gene expression; flow cytometry; RNA; DNA sequencing; genomics; lymphoma; B cells; hematopathology; Hodgkin's lymphoma; lymph nodes; Epstein Barr virus; transformation; leukaemia
Prof. Dr. Camille Laurent
Hodgkin’s lymphoma is unique amongst germinal-center B-cell derived malignant lymphomas through its presentation. The mononuclear Hodgkin and diagnostic, at least bi-nuclear Reed-Sternberg cells, count generally for only 1–3% of the total nodal cellular components. Within the same case, the nuclear volume of distinct Hodgkin cells may vary >500% and Reed-Sternberg cells may be composed from 2 up to >10 nuclei. The clinical presentation may be rapid with/without impressive B-symptoms and localized or multiple lymphadenopathies, or slow with/without B-symptoms and localized or multiple lymphadenopathies. Hodgkin’s lymphoma is associated with Epstein-Barr-virus and expression of the LMP1 oncogene in about 40–50% of cases but with considerable variability according to socio-economic status and geographic localization. Apart the constitutive NF-κB activation, aberrant Notch-signalling, JAK/STAT activation, and inactivating SOCS1 mutations, an increasing pathogenic importance of non-malignant lymphoid subpopulations as well as telomere/shelterin interactions within the tumor cells are emerging. Chemotherapy, combined chemo-radiotherapy, autologous stem-cell transplant, and recently immunotherapy, increased the cure rate in Hodgkin’s lymphoma to >80%. However, despite this therapeutic success, about 15% of patients succumb to relapsing/refractory disease. Thus, deeper understanding of the pathogenic mechanisms is still a must and a challenge.
This Special Issue will address innovative research efforts to further characterize relapsing/refractory disease at the epidemiologic, diagnostic, molecular, and therapeutic level.Prof. Dr. Hans Knecht
Prof. Dr. Camille Laurent
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.